Achieving 'marginal gains' to optimise outcomes in resectable pancreatic cancer.
Powell-Brett, Sarah Pande, Rupaly Roberts, Keith J
Powell-Brett, Sarah
Pande, Rupaly
Roberts, Keith J
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2021-04-01
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Improving outcomes among patients with resectable pancreatic cancer is one of the greatest challenges of modern medicine. Major improvements in survival will result from the development of novel therapies. However, optimising existing pathways, so that patients realise benefits of already proven treatments, presents a clear opportunity to improve outcomes in the short term. This narrative review will focus on treatments and interventions where there is a clear evidence base to improve outcomes in pancreatic cancer, and where there is also evidence of variation and under-treatment. Avoidance of preoperative biliary drainage, treatment of pancreatic exocrine insufficiency, prehabiliation and enhanced recovery after surgery, reducing perioperative complications, optimising opportunities for elderly patients to receive therapy, optimising adjuvant chemotherapy and regular surveillance after surgery are some of the strategies discussed. Each treatment or pathway change represents an opportunity for marginal gain. Accumulation of marginal gains can result in considerable benefit to patients. Given that these interventions already have evidence base, they can be realised quickly and economically.
Citation
Powell-Brett S, Pande R, Roberts KJ. Achieving 'Marginal Gains' to Optimise Outcomes in Resectable Pancreatic Cancer. Cancers (Basel). 2021 Apr 1;13(7):1669. doi: 10.3390/cancers13071669
Type
Article